With new CEO on board, Germany's Vibalogics lays out $150M for Boston viral vector site

URLhttps://www.fiercepharma.com/manufacturing/new-ceo
SourceFierce Pharma
Date Published11/11/2020
Author NameKyle Blankenship
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Vibalogics
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):250
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2024
Domestically, the work will be done:In-house
Capital investment ($):150
Country(ies) from which reshored:Germany
City reshored to:Boston
State(s) reshored to:MA
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredviral vectors and viruses for vaccines
What domestic positive factors made reshoring more attractive?Under-utilized capacity, covid-19, growing need
Find Reshoring Articles